Precision BioSearch supports Pioneer Group’s ‘Launch Accelerator’ programme
Precision BioSearch Co-founder, Malcolm Silander, will deliver a half-day seminar to 14 Founders of the UK’s most exciting early-stage biotech companies as part of the Pioneer Group Launch Accelerator programme.
Myricx Bio partners with Precision BioSearch to appoint CSO
Precision BioSearch was delighted to partner with Myricx Bio, a biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for antibody-drug conjugates (ADCs), to secure the appointment of Dr Francesca Zammarchi as Chief Scientific Officer.
Hiring with precision: candidate behaviours in a post-boom market
Biotech investment has taken a considerable downward turn over the past 18 months, impacted by the global macroeconomic situation and a return to lower levels of funding post-pandemic.
Precision BioSearch expands C-suite team of SENISCA with COO and CDO appointments
Precision BioSearch partnered with SENISCA, an award-winning biotechnology company developing RNA based therapeutics to reverse cellular senescence and target age-related disease
‘How to be an early-stage Biotech CEO in challenging times’, cited by Citeline
Our Co-founder, Malcolm Silander, chaired the discussion which formed the basis of Andrew McConaghie’s (In Vivo / Citeline) recent article, ‘How to be an early-stage Biotech CEO in challenging times’.
Precision BioSearch, corporate sponsorship of Bio Equity Europe 2023
Precision BioSearch is delighted to announce our corporate sponsorship of Bio Equity Europe 2023, being held from May 14-16th in Dublin, Ireland.
NRG Therapeutics partners with Precision BioSearch to expand management team
Precision BioSearch was pleased to partner with NRG Therapeutics, an innovative neuroscience company targeting mitochondrial dysfunction, to secure Gilles Ouvry as VP Chemistry and Vad Lazari as VP Biology.
Hiring with precision: how biotech investment headwinds impact leadership hiring
After several record years for biotech investment, the market has taken a downward turn in the past year.
Precision BioSearch secures CEO for Oxford spin-out, Dark Blue Therapeutics
Precision BioSearch partnered with Dark Blue Therapeutics, a biotech company developing a pipeline of oncology programs from the University of Oxford and therapeutics accelerator LAB282.
Pangea appoints Alleyn Plowright as VP, Drug Discovery & Preclinical Development
Precision BioSearch is delighted to congratulate Tom Coulter on his appointment as Head, Drug Discovery Programs and Partnerships with Dalriada Drug Discovery.